AU2021235055A1 - Method for treating inflammatory bowel disease II - Google Patents

Method for treating inflammatory bowel disease II Download PDF

Info

Publication number
AU2021235055A1
AU2021235055A1 AU2021235055A AU2021235055A AU2021235055A1 AU 2021235055 A1 AU2021235055 A1 AU 2021235055A1 AU 2021235055 A AU2021235055 A AU 2021235055A AU 2021235055 A AU2021235055 A AU 2021235055A AU 2021235055 A1 AU2021235055 A1 AU 2021235055A1
Authority
AU
Australia
Prior art keywords
subject
cells
stem cells
composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021235055A
Other languages
English (en)
Inventor
Silviu Itescu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900743A external-priority patent/AU2020900743A0/en
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of AU2021235055A1 publication Critical patent/AU2021235055A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2021235055A 2020-03-11 2021-03-11 Method for treating inflammatory bowel disease II Pending AU2021235055A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020900743A AU2020900743A0 (en) 2020-03-11 Method for treating inflammatory bowel disease II
AU2020900743 2020-03-11
PCT/EP2021/056193 WO2021180851A1 (en) 2020-03-11 2021-03-11 Method for treating inflammatory bowel disease ii

Publications (1)

Publication Number Publication Date
AU2021235055A1 true AU2021235055A1 (en) 2022-09-29

Family

ID=74884938

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021235055A Pending AU2021235055A1 (en) 2020-03-11 2021-03-11 Method for treating inflammatory bowel disease II

Country Status (9)

Country Link
US (1) US20230104108A1 (https=)
EP (1) EP4117623A1 (https=)
JP (1) JP2023517641A (https=)
KR (1) KR20220152240A (https=)
CN (1) CN115297875A (https=)
AU (1) AU2021235055A1 (https=)
BR (1) BR112022018022A2 (https=)
CA (1) CA3170918A1 (https=)
WO (1) WO2021180851A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
WO2021180850A1 (en) * 2020-03-11 2021-09-16 Mesoblast International Sàrl Method for treating inflammatory bowel disease i

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US20070026377A1 (en) * 2000-02-10 2007-02-01 The Regents Of The University Of California Methods for preserving nucleated mammalian cells
US8465733B2 (en) * 2007-11-02 2013-06-18 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition containing human mesenchymal stem cell
CN104873542A (zh) * 2015-05-21 2015-09-02 北京青藤谷禧干细胞科技研究院有限公司 一种脐带间充质干细胞注射液及其制备方法和应用
EP3419635B1 (en) * 2016-02-22 2022-01-05 Centauri Biotech, S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
WO2018002930A1 (en) * 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
WO2018182612A1 (en) * 2017-03-30 2018-10-04 Progenity Inc. Methods and ingestible devices for the regio-specific release of stem cells at the site of gastrointestinal tract disease
WO2021180850A1 (en) * 2020-03-11 2021-09-16 Mesoblast International Sàrl Method for treating inflammatory bowel disease i

Also Published As

Publication number Publication date
US20230104108A1 (en) 2023-04-06
EP4117623A1 (en) 2023-01-18
WO2021180851A1 (en) 2021-09-16
JP2023517641A (ja) 2023-04-26
KR20220152240A (ko) 2022-11-15
BR112022018022A2 (pt) 2022-10-18
CN115297875A (zh) 2022-11-04
CA3170918A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
US20230104108A1 (en) Method for treating inflammatory bowel disease ii
US20230165904A1 (en) Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
US20230172991A1 (en) Method for treating inflammatory bowel disease i
CA3168330A1 (en) Method for treating chronic graft versus host disease
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
US20240207323A1 (en) Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells
US20250032552A1 (en) Method of treating severe graft versus host disease
AU2024332651A1 (en) Third line treatment for gvhd
CN121985953A (en) Three-wire therapy for the treatment of GvHD
KR20260061190A (ko) GvHD에 대한 3차 치료